Dr. Jonathan Douxflis
Master in pharmaceutical sciences
PhD in biomedical and pharmaceutical sciences
Academic at the University of Namur
CEO & Founder of QUALIblood s.a.
External assessor at the AFMPS/FAGG
After being graduated in pharmaceutical sciences in 2011, Prof. Jonathan Douxfils obtained his PhD in biomedical and pharmaceutical sciences in 2015.
In 2017 he launched QUALIblood, a Contract Research Organization (CRO) aiming to provide the industries, hospitals and universities with central laboratory services for blood investigations. His company employs 10 people actively working on pre-clinical, phase-2 and phase-3 clinical trials in several pharmaceutical fields.
In 2018, he gained an academic position at the University of Namur in Belgium.
In 2019, he received the Eberhard F. Mammen Young Investigator Award for his research on the development of a new algorithm based on thrombin generation to assess hormone-related prothrombotic changes.
In 2020, he was nominated as the “Namurois of Year”, category Sciences, a price rewarding people in the Namur community for their engagement and their scientific discovery.
During the COVID pandemic, in order to counter the wave of fraudulent IVD devices that reached the market for only profit-benefit, he started several projects aiming at providing the laboratory with independent data on the performance of diagnostic assays. He started with his teams clinicals studies aiming at evaluating the serological response of COVID-19 patients and in vaccine recipients. He also started research on the risk of thrombotic events related to the cytokine storm.
The research directed by Prof. Douxfils played a leading role in the establishment of guidelines for the laboratory measurement of DOACs. These recommendations have been used so far by several Expert Societies involved in the field of thrombosis and hemostasis. He also provided his expertise for the development of a new contraceptive agent and has been actively involved in the discussion and the writing of the regulatory documents for the obtention of the marketing authorization.
He also exercised his expertise as a pharmacovigilance expert at the European Medicines Agency, has been co-chairmen of the SSC Control of Anticoagulation at the International Society of Thrombosis and Haemostasis (ISTH), is Member Expert Team Haemostasis Diagnostics at the ECAT, and he works as an Associate Editor in several scientific journals.
Passionate about clinical and laboratory research, he is involved in several projects aiming to solve pharmacological and/or epidemiological problems.
Thanks to his translational view of the pharmaceutical and medical device market from basic research to post-marketing pharmacovigilance, his collaborations with key opinion leaders but also with field practitioners, Prof. Jonathan Douxfils puts its expertise and know-how at the services of societal projects aiming to improve the safety and effectiveness of therapeutic agents in order to promote public health.